BBOT vs STRO
BBOT: BridgeBio Oncology is advancing next-generation small-molecule inhibitors of RAS and PI3K pathways for previously untreatable solid tumors including KRAS-driven lung and pancreatic cancers. STRO: Sutro Biopharma is a clinical-stage oncology firm using proprietary cell-free protein synthesis technology to develop specialized antibody-drug conjugates for cancer treatment.
Side-by-side fundamentals
| Metric | BBOT | STRO | Edge |
|---|---|---|---|
| Price as of 2026-08-06 close | $8.78 | $24.15 | |
| Market cap as of 2026-08-08 | $703M | $400M | |
| Net margin as of 2026-08-08 | n/a | -154.2% | |
| Operating margin as of 2026-08-08 | n/a | -120.0% | |
| ROE as of 2026-08-08 | -35.2% | -223.8% | BBOT higher |
| ROA as of 2026-08-08 | -32.2% | -69.2% | BBOT higher |
| Debt / equity as of 2026-08-08 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-08 | n/a | +49.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +14.8% | |
| Beta as of 2026-08-08 | 0.38 | 1.48 | |
| 1-year return as of 2026-08-06 close | -11.2% | +194.5% | STRO higher |
Fundamentals: market data, as of 2026-08-08. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-06.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.